AU Patent

AU2018282098B2 — Inhibition of crystal growth of roflumilast

Assigned to Arcutis Biotherapeutics Inc · Expires 2024-05-23 · 2y expired

What this patent protects

Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glyc…

USPTO Abstract

Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in patient in need of such treatment.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018282098B2
Jurisdiction
AU
Classification
—
Expires
2024-05-23
Drug substance claim
No
Drug product claim
No
Assignee
Arcutis Biotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.